Envigo RMS Holding Corp. has entered a collaboration with Biocytogen, a global biotech company leveraging innovative technologies, to support research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the U.S., Europe, and certain Asia-Pacific regions.
 
The triple immunodeficient B-NDG mouse model was independently designed and produced by Biocytogen. Lacking mature T cells, B cells or functional NK cells, and displaying cytokine signaling deficiencies, this mouse model is highly immunodeficient and capable of supporting human immune cell transplantation. The model is widely used in research and drug discovery in many fields including oncology, immuno-oncology, infectious disease, and stem cell biology.
 
Dr. Adrian Hardy, President and CEO of Envigo, said, “Our collaboration with Biocytogen further expands the range of models available to Envigo’s customers. The B-NDG model and future models to follow, offer a robust alternative to existing immunodeficient models for critical research and the development of life-saving therapies.”
 
Dr. Yuelei Shen, President and CEO of Biocytogen, said, “Both companies are dedicated to supply good non-clinical models for basic research and drug development. We believe that such collaboration leveraging the high quality of mouse models generated by Biocytogen and the state-of-the-art breeding facilities & health monitoring programs at Envigo can satisfy the needs in those related fields.”